| Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia. | |
| | |
MedLine Citation:
|
PMID: 6957156 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This report describes the results of long-term treatment for blood lipid regulation with a new drug, gemfibrozil (Lopid). During a short-term placebo-controlled phase, gemfibrozil had significantly reduced triglycerides, VLDL-cholesterol and the LDL-cholesterol and had significantly increased HDL-cholesterol and the HDL-cholesterol to total cholesterol ratio. It had not, however, greatly affected total cholesterol and LDL-cholesterol. In the long term phase of the study the improvement attained during the controlled phase was maintained. More important, the lipoprotein values that had not shown improvement in the controlled phase showed definite beneficial changes. The types and incidence of adverse reactions during the long term treatment were similar to those observed during the controlled period. The results of the study indicate that gemfibrozil is effective and relatively safe for the long term treatment of lipid irregularities. |
| | |
Authors:
|
J E Lewis |
Related Documents
:
|
19469266 - Influence of smoking on serum lipid and lipoprotein levels among family medicine patients. 21098376 - Lipid and transaminase concentrations after formulary conversion of niaspan to slo-niacin. 6529446 - Hyperlipemia and arteriosclerotic cardiovascular disease in the polynesian population o... 8892766 - Changes in plasma lipids and lipoproteins associated with starting or stopping postmeno... 2362896 - Coeliac disease and collagenous colitis. 4875006 - Effect of neomycin on exchangeable pools of cholesterol in the steady state. |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: Angiology Volume: 33 ISSN: 0003-3197 ISO Abbreviation: Angiology Publication Date: 1982 Sep |
Date Detail:
|
Created Date: 1982-12-02 Completed Date: 1982-12-02 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0203706 Medline TA: Angiology Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 603-12 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antilipemic Agents / administration & dosage*, therapeutic use Cholesterol / blood Cholesterol, HDL Cholesterol, LDL Cholesterol, VLDL Gemfibrozil Humans Hyperlipidemias / drug therapy* Lipoproteins, HDL / blood Lipoproteins, LDL / blood Lipoproteins, VLDL / blood Middle Aged Pentanoic Acids / administration & dosage*, therapeutic use Triglycerides / blood Valerates / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Cholesterol, VLDL; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/Lipoproteins, VLDL; 0/Pentanoic Acids; 0/Triglycerides; 0/Valerates; 25812-30-0/Gemfibrozil; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hyperlipoproteinemia, atherosclerosis and gemfibrozil.
Next Document: Effect of radiolabeled materials on tracheal mucous clearance in beagle dogs.